Voyager Therapeutics (NASDAQ: VYGR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.560 | ||||||
REV | 658.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Voyager Therapeutics (NASDAQ: VYGR) through any online brokerage.
Other companies in Voyager Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Outlook Therapeutics (NASDAQ:OTLK), AVEO Pharmaceuticals (NASDAQ:AVEO), Innate Pharma (NASDAQ:IPHA) and Impel Pharmaceuticals (NASDAQ:IMPL).
The latest price target for Voyager Therapeutics (NASDAQ: VYGR) was reported by Chardan Capital on Wednesday, November 3, 2021. The analyst firm set a price target for 4.00 expecting VYGR to fall to within 12 months (a possible -30.56% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Voyager Therapeutics (NASDAQ: VYGR) is $5.76 last updated June 28, 2022, 8:00 PM UTC.
There are no upcoming dividends for Voyager Therapeutics.
Voyager Therapeutics’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Voyager Therapeutics.
Voyager Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.